GlassScriptPhysician profile
Matthew Robert Glynn
NPI 1225508765
$3,702.24
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,428 · 2022: $1,231 · 2023: $24.95 · 2024: $17.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,044.66 | 2021-2022 | |
| Viiv Healthcare Company | $985.48 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $201.95 | 2021-2022 | |
| Abbvie INC. | $183.27 | 2021-2023 | |
| Theratechnologies INC. | $111.57 | 2021 | |
| Harmony Biosciences LLC | $98.77 | 2022 | |
| Astellas Pharma US INC | $89.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.32 | 2021-2022 | |
| Emd Serono, INC. | $87.21 | 2021-2022 | |
| Pfizer INC. | $83.01 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.78 | 2021-2022 | |
| Janssen Products, LP | $59.98 | 2021 | |
| Lilly USA, LLC | $43.37 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.13 | 2021 | |
| Alkermes, INC. | $42.07 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $41.84 | 2021 | |
| Jazz Pharmaceuticals INC. | $41.70 | 2021-2022 | |
| Novo Nordisk INC | $35.57 | 2021-2022 | |
| Eisai INC. | $34.97 | 2021-2022 | |
| Genentech USA, INC. | $33.56 | 2021 | |
| Janssen Biotech, INC. | $32.09 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.46 | 2022 | |
| Biogen, INC. | $25.19 | 2021 | |
| Glaxosmithkline, LLC. | $24.32 | 2021 | |
| Amarin Pharma, INC. | $24.16 | 2021 | |
| Napo Pharmaceuticals INC | $21.64 | 2021 | |
| Antares Pharma, INC. | $20.18 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.52 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.49 | 2024 | Dupixent |
| Phadia US INC. | $17.42 | 2021 | |
| Acerus Pharmaceuticals Corporation | $17.39 | 2022 | |
| Paratek Pharmaceuticals, INC. | $12.50 | 2021 | |
| Adlon Therapeutics L.P. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Glynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.